Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

• Main Authors: Jing Ni (Author), Xianzhong Cheng (Author), Rui Zhou (Author), Xia Xu (Author), Wenwen Guo (Author), Xiaoxiang Chen (Author)
• Format: Book
• Published: BMC, 2019-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Purpose Poly (ADP-ribose) polymerase (PARP) inhibitor, is a milestone in treatment of ovarian cancer. However, there is no real world study from China regarding the clinical outcome of the taking PARP inhibitor (PARPi), Olaparib(Lynparza™). The goal of this research is to evaluate the side...